Skip to main content
. Author manuscript; available in PMC: 2012 Oct 3.
Published in final edited form as: Cancer Res. 2010 Aug 31;70(19):7442–7454. doi: 10.1158/0008-5472.CAN-10-0247

Figure 3. TLR2-MyD88 signals in pmel CD8 T-cells enhance antitumor activity against an established melanoma tumor.

Figure 3

A) Wild type BL6 or MyD88−/− mice (D) were injected (s.c.) with B16 melanoma cells and sublethally irradiated (400 cGy) when tumors reached a size of approximately of 50 mm2. One day later mice were injected (i.v.; 1×106) with previously-activated but resting pmel, TLR2−/−pmel or MyD88−/−pmel CD8 T-cells and injected i.p. with mgp10025–33 antigen and anti-CD40 antibody in each the absence or presence of TLR2 ligand. Mice received weekly peritumioral s.c. injections of TLR2 ligand or control saline. Tumor sizes were calculated by measuring perpendicular by longitudinal diameter. Data are compiled from four (B and C) or three independent (D) experiments, each yielding identical trends; *P< 0.001.